News
  Date Title View
May 2, 2016
Company on Track to File NDA in 3Q 2016 for Rhopressa™ (netarsudil ophthalmic solution) 0.02% Mercury 1 Phase 3 Topline Readout for Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Also Expected in 3Q 2016 Conference Call and Webcast Today, May 2, at ...
Apr 25, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), (the "Company"), announced today that its first quarter 2016 financial results will be released after the market closes on Monday, May 2, 2016. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. ...
Apr 5, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that Vice...
Mar 28, 2016
First Patient Dosed in 90-Day Efficacy Trial Named Mercury 2 IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) ("Aerie" or the "Company"), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma ...
Page: FirstPrevious
4
= add release to Briefcase